Similarly, in data from the NCBI, we found that the IFFO2 expression level in rhabdomyosarcoma patients with PAX3 and FOXO1 gene fusion, which is considered a predictor of adverse results in children with rhabdomyosarcoma [73], was lower than those in patients without PAX3 and FOXO1 gene fusion (Supplementary Fig. S7A). The gene discussed is FOXO1; the disease is rhabdomyosarcoma.